NASDAQ:BCTXW BriaCell Therapeutics (BCTXW) Stock Price, News & Analysis $0.27 0.00 (0.00%) (As of 07/1/2024 ET) Add Compare Share Share Today's Range$0.21▼$0.2750-Day Range$0.24▼$0.9452-Week Range$0.17▼$3.30Volume173,794 shsAverage Volume38,583 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get BriaCell Therapeutics alerts: Email Address Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About BriaCell Therapeutics Stock (NASDAQ:BCTXW)BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCTXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTXW Stock News HeadlinesMay 28, 2024 | finance.yahoo.comBriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human StudyMay 28, 2024 | stockhouse.comBriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human StudyJuly 2, 2024 | Banyan Hill Publishing (Ad)Biden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But there’s more to this story than meets the eye.May 28, 2024 | finance.yahoo.comBriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human StudyMay 24, 2024 | finance.yahoo.comThis BriaCell Therapeutics Insider Increased Their Holding By 55% Last YearMay 16, 2024 | uk.investing.comBriacell Therapeutics Corp (BCTX)February 20, 2024 | finance.yahoo.comGet Rich Quick With These 3 Penny Stocks to Buy NowFebruary 7, 2024 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder CaseJuly 2, 2024 | Banyan Hill Publishing (Ad)Biden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But there’s more to this story than meets the eye.February 6, 2024 | finance.yahoo.comBreaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP ManufacturingJanuary 6, 2024 | theglobeandmail.comBriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)January 4, 2024 | finance.yahoo.comBriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast CancerDecember 6, 2023 | finance.yahoo.comBriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical BenefitNovember 30, 2023 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic TumorNovember 30, 2023 | finance.yahoo.comBriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic TumorOctober 18, 2023 | finance.yahoo.comBriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) ConferencesOctober 4, 2023 | finance.yahoo.comBriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast CancerAugust 25, 2023 | finance.yahoo.comBriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing ShareholdersMay 25, 2023 | finance.yahoo.comBriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.April 17, 2023 | finance.yahoo.comBriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACRApril 3, 2023 | bizjournals.comBriaCell intends to launch a spinoff to accelerate its drug development activitiesMarch 15, 2023 | finance.yahoo.comBriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual MeetingJanuary 23, 2023 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell to Investigate Alleged Illegal Trading of Public SecuritiesJanuary 10, 2023 | finance.yahoo.comBriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost EnrolmentDecember 8, 2022 | finance.yahoo.comBriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®October 21, 2022 | finance.yahoo.comBriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation ProgressingAugust 4, 2022 | finance.yahoo.comBriaCell Secures License for a Promising Novel Anti-Cancer AgentSee More Headlines Receive BCTXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BCTXW CUSIPN/A CIK1610820 WebN/A Phone604-921-1810FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 69)CEO, President & Director Comp: $785.3kMr. Gadi Levin B.Com. (Age 51)C.A., CPA, M.B.A., CFO & Corporate Secretary Comp: $304.46kDr. Miguel A. Lopez-Lago Ph.D. (Age 55)Chief Scientific Officer Comp: $298.9kDr. Giuseppe Del Priore M.D. (Age 62)M.P.H., MPH, Chief Medical Officer Comp: $492.5kDr. Charles Louis Wiseman FACP (Age 78)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Comp: $241.14kKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors BCTXW Stock Analysis - Frequently Asked Questions How have BCTXW shares performed in 2024? BriaCell Therapeutics' stock was trading at $2.50 at the beginning of the year. Since then, BCTXW shares have decreased by 89.2% and is now trading at $0.2689. View the best growth stocks for 2024 here. Are investors shorting BriaCell Therapeutics? BriaCell Therapeutics saw a decrease in short interest during the month of June. As of June 15th, there was short interest totaling 3,500 shares, a decrease of 79.3% from the May 31st total of 16,900 shares. Based on an average daily volume of 56,600 shares, the short-interest ratio is presently 0.1 days. View BriaCell Therapeutics' Short Interest. How do I buy shares of BriaCell Therapeutics? Shares of BCTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCTXW) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersBiden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But t...Banyan Hill Publishing | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredCatalyst Could Trigger 10,000% Crypto GainsFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCTXW Stock Alerts